Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Ziv Gil

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5390-9507; OpenAlex author ID A5089440321. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 10

  1. Synthetic Mimetics of Exosomal Lipid Profile Enhance Gemcitabine Delivery in Pancreatic Cancer Last author DOI 10.1101/2025.10.24.684306↗
  2. Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer. Co-author DOI 10.7150/ijbs.60473↗
  3. RET, a targetable driver of pancreatic adenocarcinoma. Last author DOI 10.1002/ijc.32040↗
  4. MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1. Co-author DOI 10.1038/s41467-019-08759-0↗
  5. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-18-0124↗
  6. Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma. Last author DOI 10.1038/onc.2016.483↗
  7. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.drup.2015.10.002↗
  8. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Last author DOI 10.1038/onc.2013.357↗
  9. Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase. First author DOI 10.4161/onci.27231↗
  10. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Last author DOI 10.1158/0008-5472.can-12-0764↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Moran Amit · 5 shared papers, 2012–2019 · strength 0.33
  2. Yoav Binenbaum · 4 shared papers, 2014–2018 · strength 0.29
  3. Tina Napso Shogan · 1 shared paper, 2025 · strength 0.27
  4. Richard J. Wong · 3 shared papers, 2012–2017 · strength 0.15
  5. Thuy Xuan Phan · 1 shared paper, 2021 · strength 0.12
  6. Marcela d'Alincourt Salazar · 1 shared paper, 2021 · strength 0.12
  7. Lifeng Yang · 1 shared paper, 2021 · strength 0.12
  8. Laleh Golkar Melstrom · 1 shared paper, 2021 · strength 0.12
  9. Paul Wong · 1 shared paper, 2021 · strength 0.12
  10. Don J. Diamond · 1 shared paper, 2021 · strength 0.12
  11. Joshua D. Rabinowitz · 1 shared paper, 2021 · strength 0.12
  12. Ying Yang · 1 shared paper, 2019 · strength 0.09
  13. Mei Kong · 1 shared paper, 2019 · strength 0.09
  14. Noam Weizman · 2 shared papers, 2012–2014 · strength 0.08
  15. Oren Cavel · 1 shared paper, 2012 · strength 0.03
  16. Yuman Fong · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.